Section 66
Chapter 65,836

Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease

Munteanu, M.; Pais, R.; Peta, V.; Deckmyn, O.; Moussalli, J.; Ngo, Y.; Rudler, M.; Lebray, P.; Charlotte, F.; Thibault, V.; Lucidarme, O.; Ngo, A.; Imbert-Bismut, F.ço.; Housset, C.; Thabut, D.; Ratziu, V.; Poynard, T.

Alimentary Pharmacology and Therapeutics 48(10): 1117-1127


ISSN/ISBN: 1365-2036
PMID: 30334263
DOI: 10.1111/apt.14990
Accession: 065835089

Download citation:  

Although the FibroTest has been validated as a biomarker to determine the stage of fibrosis in non-alcoholic fatty liver disease (NAFLD) with results similar to those in chronic hepatitis C (CHC), B (CHB), and alcoholic liver disease (ALD), it has not yet been confirmed for the prediction of liver-related death. To validate the 10-year prognostic value of FibroTest in NAFLD for the prediction of liver-related death. Patients in the prospective FibroFrance cohort who underwent a FibroTest between 1997 and 2012 were pre-included. Mortality status was obtained from physicians, hospitals or the national register. Survival analyses were based on univariate (Kaplan-Meier, log rank, AUROC) and multivariate Cox risk ratio taking into account age, sex and response to anti-viral treatment as covariates. The comparator was the performance of the FibroTest in CHC, the most validated population. 7082 patients were included; 1079, 3449, 2051, and 503 with NAFLD, CHC, CHB, and ALD, respectively. Median (range) follow-up was 6.0 years (0.1-19.3). Ten year survival (95% CI) without liver-related death in patients with NAFLD was 0.956 (0.940-0.971; 38 events) and 0.832 (0.818-0.847; 226 events; P = 0.004) in CHC. The prognostic value (AUROC / Cox risk ratio) of FibroTest in patients with NAFLD was 0.941 (0.905-0.978)/1638 (342-7839) and even higher than in patients with CHC 0.875 (0.849-0.901; P = 0.01)/2657 (993-6586). The FibroTest has a high prognostic value in NAFLD for the prediction of liver-related death. (ClinicalTrials.gov number, NCT01927133).

PDF emailed within 0-6 h: $19.90